Catalog No.: PC-24942Not For Human Use, Lab Use Only.
LCKLSL (Leu-Cys-Lys-Leu-Ser-Leu) is a potent, specific hexapeptide competitive inhibitor of Annexin A2 (AnxA2), inhibits tissue plasminogen activator (tPA)-binding capacity with IC50 of 11 uM.
LCKLSL (Leu-Cys-Lys-Leu-Ser-Leu) is a potent, specific hexapeptide competitive inhibitor of Annexin A2 (AnxA2), inhibits tissue plasminogen activator (tPA)-binding capacity with IC50 of 11 uM. LCKLSL targets the N-terminal tPA-binding site of AnxA2, binds efficiently to cell-surface AnxA2 compared with binding of the control peptide LGKLSL. LCKLSL inhibits the generation of plasmin and suppresses the VEGF-induced activity of tPA under hypoxic conditions. LCKLSL prevents hypoxia-induced angiogenic events in in vivo models of angiogenesis.
Physicochemical Properties
M.Wt
675.89
Formula
C30H57N7O8S
Appearance
Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility
10 mM in DMSO
Chemical Name/SMILES
AA sequence: Leu-Cys-Lys-Leu-Ser-Leu
References
1. Hajjar KA, et al. J Biol Chem. 1998 Apr 17;273(16):9987-93.
2. Valapala M, et al. J Cell Sci. 2011 May 1;124(Pt 9):1453-64.
